WALTHAM, Mass., Feb. 4, 2014 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced it will report unaudited consolidated financial results for the fourth quarter and year ended December 31, 2013 before the U.S. financial markets open on Thursday, February 6, 2014. The announcement will be followed by a conference call and webcast with slides at 8:00 a.m. ET during which management will discuss the company's financial results, commercial progress and development programs.
To access the conference call via telephone, please dial (877) 412-6083 from the United States or (702) 495-1202 for international access. A telephone replay will be available from approximately 11:00 a.m. ET on February 6, 2014 through midnight on February 13, 2014. To access a replay of the conference call, dial (855) 859-2056 from the United States or (404) 537-3406 for international access. The pass code for the live call and the replay is 58720931.
The call will be webcast with slides and accessible through the Investors section of the company's website at www.amagpharma.com. The webcast replay will be available from approximately 11:00a.m. ET on February 6, 2014 through midnight March 7, 2014.
AMAG Pharmaceuticals, Inc. is a specialty pharmaceutical company that markets Feraheme® (ferumoxytol) Injection and MuGard® Mucoadhesive Oral Wound Rinse in the United States. Along with driving organic growth of its products, AMAG intends to expand its portfolio with additional commercial-stage specialty products. The company is seeking complementary products that leverage the company's commercial footprint and focus on hematology and oncology centers and hospital infusion centers. For additional company information, please visit www.amagpharma.com.
AMAG Pharmaceuticals and Feraheme are registered trademarks of AMAG Pharmaceuticals, Inc. MuGard® is a registered trademark of Access Pharmaceuticals, Inc.
CONTACT: AMAG Pharmaceuticals, Inc. Contact: Amy Sullivan, 617-498-3303
Source:AMAG Pharmaceuticals, Inc.